biontech
receive
funding
german
federal
ministry
education
research
support
vaccine
program
mainz
germany
globe
newswire
german
federal
ministry
education
research
bmbf
initiative
supports
accelerated
vaccine
development
well
upscaling
manufacturing
capabilities
germany
five
eight
milestones
defined
bmbf
funding
vaccine
program
already
achieved
participants
already
enrolled
phase
clinical
trial
currently
conducted
united
states
brazil
argentina
europe
mainz
germany
september
biontech
se
nasdaq
bntx
biontech
company
today
announced
receive
grant
million
euro
initiative
german
federal
ministry
education
research
bmbf
support
accelerated
development
vaccines
biontech
use
bmbf
funding
support
contribution
company
mrna
vaccine
program
partners
pfizer
fosun
pharma
respectively
goal
initiative
expansion
vaccine
development
manufacturing
capabilities
germany
well
expansion
number
participants
clinical
trials
vaccine
program
one
three
programs
supported
bmbf
initiative
provide
total
million
euro
funding
recipients
grateful
significant
support
bmbf
helping
us
provide
safe
effective
vaccine
soon
possible
following
regulatory
approval
funding
important
contribution
accelerate
development
vaccine
manufacturing
capacities
germany
highlights
tremendous
importance
mission
efficiently
find
lasting
solution
control
pandemic
said
ugur
sahin
ceo
biontech
biontech
use
grant
funding
cover
expenses
related
vaccine
program
within
funded
project
order
advance
clinical
evaluation
potential
marketing
authorisation
soon
possible
pfizer
continue
independently
fund
share
development
costs
without
use
government
funding
milestones
defined
bmbf
include
preclinical
evaluation
vaccine
candidates
initiation
implementation
clinical
phase
phase
trials
includes
four
clinical
development
milestones
upscaling
production
capacities
supply
clinical
trials
general
population
pending
marketing
authorisation
submission
regulatory
approval
well
future
marketing
authorisation
vaccine
company
already
achieved
five
eight
defined
milestones
recently
biontech
received
approval
german
regulatory
authority
initiate
german
arm
global
phase
trial
patient
recruitment
commenced
three
continents
participants
already
enrolled
worldwide
study
sites
united
states
brazil
argentina
europe
potential
marketing
authorisation
dependent
final
outcome
ongoing
clinical
trials
biontech
biopharmaceutical
new
technologies
next
generation
immunotherapy
company
pioneering
novel
therapies
cancer
serious
diseases
company
exploits
wide
array
computational
discovery
therapeutic
drug
platforms
rapid
development
novel
biopharmaceuticals
broad
portfolio
oncology
product
candidates
includes
individualized
therapies
innovative
chimeric
antigen
receptor
cells
checkpoint
targeted
cancer
antibodies
small
molecules
based
deep
expertise
mrna
vaccine
development
manufacturing
capabilities
biontech
collaborators
developing
multiple
mrna
vaccine
candidates
range
infectious
diseases
alongside
diverse
oncology
pipeline
biontech
established
broad
set
relationships
multiple
global
pharmaceutical
collaborators
including
genmab
sanofi
bayer
animal
health
genentech
member
roche
group
regeneron
genevant
fosun
pharma
pfizer
information
please
visit
biontech
statements
press
release
contains
statements
biontech
within
meaning
private
securities
litigation
reform
act
statements
may
include
may
limited
statements
concerning
biontech
efforts
combat
timing
initiate
clinical
trials
size
clinical
trials
anticipated
publication
data
clinical
trials
potential
safety
efficacy
timing
potential
emergency
use
authorizations
approvals
potential
safety
efficacy
statements
press
release
based
biontech
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
competition
create
vaccine
ability
produce
comparable
clinical
results
larger
diverse
clinical
trials
ability
effectively
scale
productions
capabilities
potential
difficulties
discussion
risks
uncertainties
see
biontech
annual
report
form
filed
sec
march
available
sec
website
information
press
release
date
release
biontech
undertakes
duty
update
information
unless
required
law
biontech
contacts
media
relations
jasmina
alatovic
media
investor
relations
sylke
maas
investors
attachment
biontech
contacts
media
relations
jasmina
alatovic
media
investor
relations
sylke
maas
investors
